An examination of layoffs in pharmaceutical and biotechnology companies in Q3 shows that as the summer progressed, the number ...
On 9 September the US House of Representatives passed the draft of the Biosecure Act, which aims to prohibit US pharma ...
Gilead Merger AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American ...
VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade to ...
The company described the move as a “mass layoff of its sales representatives and related employees across the country,” ...
Here is the complete list of stocks exiting their IPO lock-in period between October 8, 2024, and December 31, 2024 ...
Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and why complete response letters are a good contrarian buying ...
Patient groups should be playing a central role in Canada's health-care system, advocating for their members by promoting the ...
Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.
The partnership will combine Real Chemistry’s consultative and strategic expertise with Corval’s commercialization planning ...
According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.
Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement ...